Risk Adjustment Vs Readmission Risk
A precise buyer's guide for choosing between these two intelligence assets. Both solve real operational problems — but for different buyers, different workflows, and different financial objectives. Use this comparison to identify which dataset fits your specific need, then go directly to the purchase or sample page.
How to Think About This Comparison
Medicare Advantage Risk Adjustment Dataset (MARAD)
Choose MARAD when the goal is capturing revenue accurately representing the clinical complexity of your enrolled population through HCC coding and RAF score optimization. MARAD is a revenue intelligence tool.
Readmission Risk Intelligence Dataset (RRID)
Choose RRID when the goal is reducing the cost and quality impact of avoidable hospital readmissions through better post-discharge care management and transitional care. RRID is a cost reduction and quality improvement tool.
Recommended Dataset Purchase Paths
Medicare Advantage Risk Adjustment Dataset (MARAD)
Use MARAD when the question is: 'Are we accurately coding and being appropriately paid for our members' clinical complexity?' Best for MA finance and risk adjustment teams.
Readmission Risk Intelligence Dataset (RRID)
Use RRID when the question is: 'Which discharged members are most likely to be readmitted, and how do we intervene before they are?' Best for case management, quality, and population health teams.
Buyer Decision Matrix
| Dataset | When It Fits | Next Step |
|---|---|---|
| Medicare Advantage Risk Adjustment Dataset (MARAD) | Revenue capture: HCC coding completeness, RAF gap closure, RADV audit preparation. | Purchase Page |
| Readmission Risk Intelligence Dataset (RRID) | Cost reduction: 30-day readmission risk scoring, TCM enrollment prioritization, HRRP penalty avoidance. | Purchase Page |
Commercial Recommendation
For MA plans and health systems operating under value-based contracts, both datasets contribute to the same goal — better clinical and financial performance. MARAD optimizes the revenue side; RRID reduces the cost side. Many complex MA members appear in both datasets.